Primary Endpoints In Phase-3 Clinical Study

Sumitomo Pharma

11/09/2023 16:01

Sept 11 (Reuters) - Sumitomo Pharma Co Ltd  4506.T :
    * SUMITOMO PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM
PHASE 3
CLINICAL STUDIES EVALUATING VIBEGRON IN MEN WITH OVERACTIVE
BLADDER SYMPTOMS RECEIVING PHARMACOLOGICAL THERAPY FOR BENIGN
PROSTATIC HYPERPLASIA
    * SUMITOMO PHARMA CO LTD: VIBEGRON MET BOTH CO-PRIMARY
ENDPOINTS
    * SUMITOMO PHARMA CO LTD - VIBEGRON MET ALL SECONDARY
ENDPOINTS,
INCLUDING A REDUCTION IN NOCTURIA EPISODES VERSUS PLACEBO AT
WEEK 12-
    * SUMITOMO PHARMA: VIBEGRON WELL-TOLERATED, SHOWED
CONSISTENT
SAFETY PROFILE WITH NO NEW SAFETY SIGNALS COMPARED TO PRIOR
OVERACTIVE BLADDER STUDIES

Source text for Eikon:  ID:nPnnnNlha 
Further company coverage:  4506.T 

 ((reuters.briefs@thomsonreuters.com;))